Viviane Monges
Known title: DirectorCIK: 0001838204
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ADC Therapeutics Announces $86.6M Financing and Loan Amendments. ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.
Transaction History
| PHVS | ▲ Buy | Option Exercise | 11,969 | $96K | 9/23/2026 | View on chart |
| PHVS | ▼ Sell | Open Market | 11,969 | $396K | 9/23/2026 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 2,596 | $8K | 6/3/2026 | View on chart |
| ADCT | ▲ Buy | Grant | 45,000 | $0 | 6/1/2026 | View on chart |
| PHVS | ▼ Sell | Open Market | 9,667 | $293K | 5/21/2026 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 2,584 | $9K | 6/13/2025 | View on chart |
| ADCT | ▲ Buy | Grant | 40,000 | $0 | 6/3/2025 | View on chart |
| ADCT | ▼ Sell | Open Market | 1,437 | $4K | 6/17/2024 | View on chart |
| ADCT | ▲ Buy | Grant | 40,000 | $0 | 6/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Pharvaris publishes Phase 3 deucrictibant data in The Lancet
Pharvaris reported Phase 3 results for deucrictibant IR in The Lancet, showing symptom relief in 1.28 hours and complete resolution in 11.95 hours for HAE attacks. The company stated that the New Drug Application and Marketing Authorization Application are currently under review. Additional real-world data on patient preferences was also published, providing context for the treatment strategy.
Pharvaris publishes Phase 3 deucrictibant data in The Lancet. Pharvaris reported Phase 3 results for deucrictibant IR in The Lancet, showing symptom relief in 1.28 hours and complete resolution in 11.95 hours for HAE attacks. The company stated that the New Drug Application and Marketing Authorization Application are currently under review. Additional real-world data on patient preferences was also published, providing context for the treatment strategy.